Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology
Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still re...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Molina-Moya, B. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Springer Science+Business Media New York 2014 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Current treatment options in infectious diseases - Philadelphia, Pa. : Current Science, 2014, 6(2014), 4 vom: 24. Okt., Seite 377-391 |
|---|---|
| Übergeordnetes Werk: |
volume:6 ; year:2014 ; number:4 ; day:24 ; month:10 ; pages:377-391 |
| Links: |
|---|
| DOI / URN: |
10.1007/s40506-014-0034-0 |
|---|
| Katalog-ID: |
SPR036553786 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR036553786 | ||
| 003 | DE-627 | ||
| 005 | 20230519142620.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40506-014-0034-0 |2 doi | |
| 035 | |a (DE-627)SPR036553786 | ||
| 035 | |a (SPR)s40506-014-0034-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Molina-Moya, B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media New York 2014 | ||
| 520 | |a Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. | ||
| 650 | 4 | |a IFN-γ release assays |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tuberculin skin test |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Latent tuberculosis infection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Molecular detection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Molecular resistance testing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tuberculosis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Latorre, I. |4 aut | |
| 700 | 1 | |a Lacoma, A. |4 aut | |
| 700 | 1 | |a Prat, C. |4 aut | |
| 700 | 1 | |a Domínguez, J. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current treatment options in infectious diseases |d Philadelphia, Pa. : Current Science, 2014 |g 6(2014), 4 vom: 24. Okt., Seite 377-391 |w (DE-627)355400057 |w (DE-600)2090725-4 |x 1534-6250 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2014 |g number:4 |g day:24 |g month:10 |g pages:377-391 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40506-014-0034-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2070 | ||
| 912 | |a GBV_ILN_2086 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2014 |e 4 |b 24 |c 10 |h 377-391 | ||
| author_variant |
b m m bmm i l il a l al c p cp j d jd |
|---|---|
| matchkey_str |
article:15346250:2014----::eetdacsnueclssigoiirsn |
| hierarchy_sort_str |
2014 |
| publishDate |
2014 |
| allfields |
10.1007/s40506-014-0034-0 doi (DE-627)SPR036553786 (SPR)s40506-014-0034-0-e DE-627 ger DE-627 rakwb eng Molina-Moya, B. verfasserin aut Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media New York 2014 Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. IFN-γ release assays (dpeaa)DE-He213 Tuberculin skin test (dpeaa)DE-He213 Latent tuberculosis infection (dpeaa)DE-He213 Molecular detection (dpeaa)DE-He213 Molecular resistance testing (dpeaa)DE-He213 Tuberculosis (dpeaa)DE-He213 Latorre, I. aut Lacoma, A. aut Prat, C. aut Domínguez, J. aut Enthalten in Current treatment options in infectious diseases Philadelphia, Pa. : Current Science, 2014 6(2014), 4 vom: 24. Okt., Seite 377-391 (DE-627)355400057 (DE-600)2090725-4 1534-6250 nnns volume:6 year:2014 number:4 day:24 month:10 pages:377-391 https://dx.doi.org/10.1007/s40506-014-0034-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2014 4 24 10 377-391 |
| spelling |
10.1007/s40506-014-0034-0 doi (DE-627)SPR036553786 (SPR)s40506-014-0034-0-e DE-627 ger DE-627 rakwb eng Molina-Moya, B. verfasserin aut Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media New York 2014 Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. IFN-γ release assays (dpeaa)DE-He213 Tuberculin skin test (dpeaa)DE-He213 Latent tuberculosis infection (dpeaa)DE-He213 Molecular detection (dpeaa)DE-He213 Molecular resistance testing (dpeaa)DE-He213 Tuberculosis (dpeaa)DE-He213 Latorre, I. aut Lacoma, A. aut Prat, C. aut Domínguez, J. aut Enthalten in Current treatment options in infectious diseases Philadelphia, Pa. : Current Science, 2014 6(2014), 4 vom: 24. Okt., Seite 377-391 (DE-627)355400057 (DE-600)2090725-4 1534-6250 nnns volume:6 year:2014 number:4 day:24 month:10 pages:377-391 https://dx.doi.org/10.1007/s40506-014-0034-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2014 4 24 10 377-391 |
| allfields_unstemmed |
10.1007/s40506-014-0034-0 doi (DE-627)SPR036553786 (SPR)s40506-014-0034-0-e DE-627 ger DE-627 rakwb eng Molina-Moya, B. verfasserin aut Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media New York 2014 Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. IFN-γ release assays (dpeaa)DE-He213 Tuberculin skin test (dpeaa)DE-He213 Latent tuberculosis infection (dpeaa)DE-He213 Molecular detection (dpeaa)DE-He213 Molecular resistance testing (dpeaa)DE-He213 Tuberculosis (dpeaa)DE-He213 Latorre, I. aut Lacoma, A. aut Prat, C. aut Domínguez, J. aut Enthalten in Current treatment options in infectious diseases Philadelphia, Pa. : Current Science, 2014 6(2014), 4 vom: 24. Okt., Seite 377-391 (DE-627)355400057 (DE-600)2090725-4 1534-6250 nnns volume:6 year:2014 number:4 day:24 month:10 pages:377-391 https://dx.doi.org/10.1007/s40506-014-0034-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2014 4 24 10 377-391 |
| allfieldsGer |
10.1007/s40506-014-0034-0 doi (DE-627)SPR036553786 (SPR)s40506-014-0034-0-e DE-627 ger DE-627 rakwb eng Molina-Moya, B. verfasserin aut Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media New York 2014 Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. IFN-γ release assays (dpeaa)DE-He213 Tuberculin skin test (dpeaa)DE-He213 Latent tuberculosis infection (dpeaa)DE-He213 Molecular detection (dpeaa)DE-He213 Molecular resistance testing (dpeaa)DE-He213 Tuberculosis (dpeaa)DE-He213 Latorre, I. aut Lacoma, A. aut Prat, C. aut Domínguez, J. aut Enthalten in Current treatment options in infectious diseases Philadelphia, Pa. : Current Science, 2014 6(2014), 4 vom: 24. Okt., Seite 377-391 (DE-627)355400057 (DE-600)2090725-4 1534-6250 nnns volume:6 year:2014 number:4 day:24 month:10 pages:377-391 https://dx.doi.org/10.1007/s40506-014-0034-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2014 4 24 10 377-391 |
| allfieldsSound |
10.1007/s40506-014-0034-0 doi (DE-627)SPR036553786 (SPR)s40506-014-0034-0-e DE-627 ger DE-627 rakwb eng Molina-Moya, B. verfasserin aut Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology 2014 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Springer Science+Business Media New York 2014 Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. IFN-γ release assays (dpeaa)DE-He213 Tuberculin skin test (dpeaa)DE-He213 Latent tuberculosis infection (dpeaa)DE-He213 Molecular detection (dpeaa)DE-He213 Molecular resistance testing (dpeaa)DE-He213 Tuberculosis (dpeaa)DE-He213 Latorre, I. aut Lacoma, A. aut Prat, C. aut Domínguez, J. aut Enthalten in Current treatment options in infectious diseases Philadelphia, Pa. : Current Science, 2014 6(2014), 4 vom: 24. Okt., Seite 377-391 (DE-627)355400057 (DE-600)2090725-4 1534-6250 nnns volume:6 year:2014 number:4 day:24 month:10 pages:377-391 https://dx.doi.org/10.1007/s40506-014-0034-0 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 6 2014 4 24 10 377-391 |
| language |
English |
| source |
Enthalten in Current treatment options in infectious diseases 6(2014), 4 vom: 24. Okt., Seite 377-391 volume:6 year:2014 number:4 day:24 month:10 pages:377-391 |
| sourceStr |
Enthalten in Current treatment options in infectious diseases 6(2014), 4 vom: 24. Okt., Seite 377-391 volume:6 year:2014 number:4 day:24 month:10 pages:377-391 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
IFN-γ release assays Tuberculin skin test Latent tuberculosis infection Molecular detection Molecular resistance testing Tuberculosis |
| isfreeaccess_bool |
false |
| container_title |
Current treatment options in infectious diseases |
| authorswithroles_txt_mv |
Molina-Moya, B. @@aut@@ Latorre, I. @@aut@@ Lacoma, A. @@aut@@ Prat, C. @@aut@@ Domínguez, J. @@aut@@ |
| publishDateDaySort_date |
2014-10-24T00:00:00Z |
| hierarchy_top_id |
355400057 |
| id |
SPR036553786 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036553786</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519142620.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40506-014-0034-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036553786</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40506-014-0034-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Molina-Moya, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer Science+Business Media New York 2014</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IFN-γ release assays</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tuberculin skin test</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Latent tuberculosis infection</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular detection</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular resistance testing</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tuberculosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Latorre, I.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lacoma, A.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prat, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Domínguez, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current treatment options in infectious diseases</subfield><subfield code="d">Philadelphia, Pa. : Current Science, 2014</subfield><subfield code="g">6(2014), 4 vom: 24. Okt., Seite 377-391</subfield><subfield code="w">(DE-627)355400057</subfield><subfield code="w">(DE-600)2090725-4</subfield><subfield code="x">1534-6250</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:4</subfield><subfield code="g">day:24</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:377-391</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40506-014-0034-0</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2014</subfield><subfield code="e">4</subfield><subfield code="b">24</subfield><subfield code="c">10</subfield><subfield code="h">377-391</subfield></datafield></record></collection>
|
| author |
Molina-Moya, B. |
| spellingShingle |
Molina-Moya, B. misc IFN-γ release assays misc Tuberculin skin test misc Latent tuberculosis infection misc Molecular detection misc Molecular resistance testing misc Tuberculosis Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology |
| authorStr |
Molina-Moya, B. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)355400057 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1534-6250 |
| topic_title |
Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology IFN-γ release assays (dpeaa)DE-He213 Tuberculin skin test (dpeaa)DE-He213 Latent tuberculosis infection (dpeaa)DE-He213 Molecular detection (dpeaa)DE-He213 Molecular resistance testing (dpeaa)DE-He213 Tuberculosis (dpeaa)DE-He213 |
| topic |
misc IFN-γ release assays misc Tuberculin skin test misc Latent tuberculosis infection misc Molecular detection misc Molecular resistance testing misc Tuberculosis |
| topic_unstemmed |
misc IFN-γ release assays misc Tuberculin skin test misc Latent tuberculosis infection misc Molecular detection misc Molecular resistance testing misc Tuberculosis |
| topic_browse |
misc IFN-γ release assays misc Tuberculin skin test misc Latent tuberculosis infection misc Molecular detection misc Molecular resistance testing misc Tuberculosis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Current treatment options in infectious diseases |
| hierarchy_parent_id |
355400057 |
| hierarchy_top_title |
Current treatment options in infectious diseases |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)355400057 (DE-600)2090725-4 |
| title |
Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology |
| ctrlnum |
(DE-627)SPR036553786 (SPR)s40506-014-0034-0-e |
| title_full |
Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology |
| author_sort |
Molina-Moya, B. |
| journal |
Current treatment options in infectious diseases |
| journalStr |
Current treatment options in infectious diseases |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
txt |
| container_start_page |
377 |
| author_browse |
Molina-Moya, B. Latorre, I. Lacoma, A. Prat, C. Domínguez, J. |
| container_volume |
6 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Molina-Moya, B. |
| doi_str_mv |
10.1007/s40506-014-0034-0 |
| title_sort |
recent advances in tuberculosis diagnosis: igras and molecular biology |
| title_auth |
Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology |
| abstract |
Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. © Springer Science+Business Media New York 2014 |
| abstractGer |
Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. © Springer Science+Business Media New York 2014 |
| abstract_unstemmed |
Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required. © Springer Science+Business Media New York 2014 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
4 |
| title_short |
Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology |
| url |
https://dx.doi.org/10.1007/s40506-014-0034-0 |
| remote_bool |
true |
| author2 |
Latorre, I. Lacoma, A. Prat, C. Domínguez, J. |
| author2Str |
Latorre, I. Lacoma, A. Prat, C. Domínguez, J. |
| ppnlink |
355400057 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s40506-014-0034-0 |
| up_date |
2024-07-03T18:19:28.643Z |
| _version_ |
1803582983263748096 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036553786</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519142620.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40506-014-0034-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036553786</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40506-014-0034-0-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Molina-Moya, B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recent Advances in Tuberculosis Diagnosis: IGRAs and Molecular Biology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Springer Science+Business Media New York 2014</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Opinion statement Tuberculosis (TB) is one of the most deadly, curable infectious diseases. In 2012, the World Health Organization (WHO) reported 8.6 million new TB cases and 1.3 million deaths. Despite intensive research to improve tuberculosis diagnosis and drug susceptibility testing, TB still remains one of the most threatening curable infectious diseases. Effective control of TB remains in prevention, the immediate detection of Mycobacterium tuberculosis and rapid detection of drug-resistant strains, followed by prompt implementation of an adequate anti-tuberculous therapy. Providing rapid antibiotic resistance detection systems is essential to treat accurately the patients, especially with the emergence and spread of drug-resistant TB. In 2012, WHO reported 84,000 confirmed multi-drug-resistant TB cases worldwide, and 9.6 % of these cases were extensively drug-resistant TB. However, conventional techniques for culture isolation and antibiotic susceptibility testing are slow. In recent years, the molecular basis of resistance to anti-tuberculous drugs has been elucidated. Molecular methods based on sequencing have been used to detect the main mutations involved in resistance from isolated strains and clinical samples. New molecular methods have been developed to detect the most common mutations conferring M. tuberculosis resistance. Furthermore, the diagnosis of the latently infected people allows measures to prevent them from developing the active disease, and thus help break the chain of transmission of the microorganism. The tuberculin skin test, the classical method for diagnosing latent TB infection, has several drawbacks: low specificity, and also a low sensitivity in immunosuppresed patients. The development of the IFN-γ release assays (IGRAs), with a recognized higher specificity, has improved the diagnosis of latent TB infection. However, for the correct use and interpretation a close cooperation between physicians and expert microbiologists is required.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IFN-γ release assays</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tuberculin skin test</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Latent tuberculosis infection</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular detection</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular resistance testing</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tuberculosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Latorre, I.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lacoma, A.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prat, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Domínguez, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Current treatment options in infectious diseases</subfield><subfield code="d">Philadelphia, Pa. : Current Science, 2014</subfield><subfield code="g">6(2014), 4 vom: 24. Okt., Seite 377-391</subfield><subfield code="w">(DE-627)355400057</subfield><subfield code="w">(DE-600)2090725-4</subfield><subfield code="x">1534-6250</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:4</subfield><subfield code="g">day:24</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:377-391</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40506-014-0034-0</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">2014</subfield><subfield code="e">4</subfield><subfield code="b">24</subfield><subfield code="c">10</subfield><subfield code="h">377-391</subfield></datafield></record></collection>
|
| score |
7.39983 |